Longboard Pharmaceuticals, Inc. (LBPH) |
|
4.15 -0.19 (-4.38%)
|
03-24 16:00 |
|
Open: |
4.24 |
Pre. Close: |
4.34 |
|
High:
|
4.38 |
Low:
|
4.041 |
|
Volume:
|
7,988 |
Market Cap:
|
94(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:27:37 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 5.85 One year: 6.7 |
| Support: |
Support1: 3.83 Support2: 3.19 |
| Resistance: |
Resistance1: 5.01 Resistance2: 5.73 |
| Pivot: |
4.59  |
| Moving Average: |
MA(5): 4.31  MA(20): 4.74
MA(100): 4.68 MA(250): 4.29 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 21.5 %D(3): 24.6 |
| RSI: |
RSI(14): 41.1 |
| 52-week: |
High: 6.23 Low: 2.7 |
| Average Vol(K): |
3-Month: 29 (K) 10-Days: 24 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LBPH ] has closed above bottom band by 23.0%. Bollinger Bands are 4.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.39 - 4.41 |
4.41 - 4.43 |
|
Low:
|
3.98 - 4.01 |
4.01 - 4.03 |
|
Close:
|
4.1 - 4.14 |
4.14 - 4.18 |
|
Company Description |
|
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. |
Headline News |
Fri, 17 Mar 2023
HC Wainwright Research Analysts Decrease Earnings Estimates for ... - MarketBeat
Mon, 06 Mar 2023
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Q4 2022 Earnings Call Transcript - Yahoo Finance
Thu, 02 Mar 2023
Longboard Pharmaceuticals Reports Full Year 2022 Financial ... - Business Wire
Thu, 23 Feb 2023
Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023 - Yahoo Finance
Tue, 07 Feb 2023
Longboard Pharmaceuticals Announces Pricing of Public Offering of ... - Business Wire
Sun, 25 Dec 2022
We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
14 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
25.1 (%) |
|
% Held by Institutions
|
43.6 (%) |
|
Shares Short
|
18 (K) |
|
Shares Short P.Month
|
18 (K) |
Stock Financials |
|
EPS
|
-2.63 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
6.61 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-26.7 |
|
Return on Equity (ttm)
|
-45.1 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-34 (M) |
|
Levered Free Cash Flow
|
-20 (M) |
Stock Valuations |
|
PE Ratio
|
-1.59 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.62 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.66 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
